HEALTH TECHNOLOGY ASSESSMENT AND PERSONALIZED MEDICINE: ARE ECONOMIC EVALUATION GUIDELINES SUFFICIENT TO SUPPORT DECISION MAKING?
- 1 April 2014
- journal article
- research article
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 30 (2), 179-187
- https://doi.org/10.1017/s0266462314000142
Abstract
Background: Many jurisdictions delivering health care, including Canada, have developed guidance for conducting economic evaluation, often in the service of larger health technology assessment (HTA) and reimbursement processes. Like any health intervention, personalized medical (PM) interventions have costs and consequences that must be considered by reimbursement authorities with limited resources. However, current approaches to economic evaluation to support decision making have been largely developed from population-based approaches to therapy—that is, evaluating the costs and consequences of single interventions across single populations. This raises the issue as to whether these methods, as they are or more refined, are adequate to address more targeted approaches to therapy, or whether a new paradigm for assessing value in PM is required.Objectives: We describe specific issues relevant to the economic evaluation of diagnostics-based PM and assess whether current guidance for economic evaluation is sufficient to support decision making for PM interventions.Methods: Issues were identified through literature review and informal interviews with national and international experts (n = 10) in these analyses. This article elaborates on findings and discussion at a workshop held in Ottawa, Canada, in January 2012.Results: Specific issues related to better guiding economic evaluation of personalized medicine interventions include: how study questions are developed, populations are characterized, comparators are defined, effectiveness is evaluated, outcomes are valued and how resources are measured. Diagnostics-based PM also highlights the need for analyses outside of economic evaluation to support decision making.Conclusions: The consensus of this group of experts is that the economic evaluation of diagnostics-based PM may not require a new paradigm. However, greater complexity means that existing approaches and tools may require improvement to undertake these more analyses.Keywords
This publication has 27 references indexed in Scilit:
- Current Methodological Issues in the Economic Assessment of Personalized MedicineValue in Health, 2013
- Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancerBMC Cancer, 2012
- Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest GroupValue in Health, 2012
- Cost-Utility Analyses of Diagnostic Laboratory Tests: A Systematic ReviewValue in Health, 2011
- Economics of individualization in comparative effectiveness research and a basis for a patient-centered health careJournal of Health Economics, 2011
- Do Economic Evaluations of Targeted Therapy Provide Support for Decision Makers?Journal of Oncology Practice, 2011
- Cost Effectiveness of PharmacogenomicsPharmacoEconomics, 2010
- The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working GroupGenetics in Medicine, 2009
- Value of Information on Preference Heterogeneity and Individualized CareMedical Decision Making, 2007
- Valuing the benefits and costs of health care programmes: where's the ‘extra’ in extra-welfarism?Social Science & Medicine, 2003